ArticleFrontiers in pediatrics2025
Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of matrix metalloproteinases in the invasion of glioblastoma and drug interventions (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous Thromboembolism (VTE) is a significant complication in pediatric high-grade glioma (pHGG) patients, impacting prognosis and treatment outcomes. Identifying unique risk factors and pathophysiology in children is essential for targeted prevention and treatment. Methods: A multicenter retrospective analysis was conducted on pHGG patients enrolled between January 2012 and January 2024 at two hospitals. Data were collected from electronic medical records and follow-ups, focusing on VTE occurrence, clinical characteristics, and treatment outcomes. Statistical analyses included Results: Out of 216 screened patients, 168 met the inclusion criteria. The mean age was 9.87 ± 3.67 years, with 37.5% experiencing VTE. Tumor volume, grade, and specific genetic mutations significantly influenced VTE occurrence. Anticoagulation therapy, Isocitrate Dehydrogenase 1 (IDH1) mutations, O6-Methylguanine-DNA Methyltransferase (MGMT) methylation, radiotherapy, chemotherapy, and prolonged bed rest were protective against VTE, while increased tumor volume, Grade 4 glioma, Epidermal Growth Factor Receptor (EGFR) positivity, p53 mutations, glucocorticoid therapy and central venous catheter placement (CVCP) placement promoted VTE risk. The median survival time was 51.4 months, and VTE occurrence negatively impacted patient prognosis. Conclusion: This study highlights the risk factors for VTE in pHGG patients, emphasizing the need for tailored prevention and treatment strategies. The findings underscore the importance of clinical characteristics, genetic profiles, and treatment modalities in managing VTE and improving survival outcomes in pHGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.